Physician profile
Mark S Brown
NPI 1467491050
$7,481.69
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,309 · 2020: $1,839 · 2021: $2,094 · 2022: $127 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $112.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,116.45 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $884.05 | 2019-2021 | |
| Abbvie INC. | $590.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $444.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $442.91 | 2019-2021 | |
| Pfizer INC. | $432.99 | 2019-2022 | |
| Amarin Pharma, INC. | $408.85 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $286.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $275.60 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $200.28 | 2019 | |
| Lilly USA, LLC | $191.95 | 2019-2021 | |
| Astellas Pharma US INC | $187.32 | 2019-2021 | |
| Novo Nordisk INC | $169.22 | 2019-2021 | |
| Insmed, INC. | $161.02 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.